Aim The aim of this study was to evaluate the pharmacokinetic profile of donepezil HCl (5 mg) in patients with impaired hepatic function, following the administration of single oral doses.
Introduction
donepezil is of primary importance, as donepezil is orally administered and subject to extensive first-pass metabolism. Donepezil HCl (also known as E2020 or AriceptA, the In addition, both pre-clinical and clinical studies have registered trademark of Eisai Co. Ltd, Tokyo, Japan), a demonstrated that donepezil is metabolized primarily in the piperidine, is a highly selective inhibitor of the enzyme liver [6] [7] [8] [9] [10] [11] . In vitro studies using human hepatic microsomes acetylcholinesterase (AChE) [1, 2] that is chemically unique have shown that the cytochrome P-450 isoenzyme CYP-3A4 from other AChE inhibitors [3, 4] . In vitro and pre-clinical is mostly responsible for the metabolism of donepezil, with studies have demonstrated that donepezil is approximately CYP-2D6 playing a minor role. With this in mind, this 1200 times more selective for AChE in the brain than for study was designed to assess the effects of compromised butyrylcholinesterase (BuChE) in the periphery [1, 2, 5] .
hepatic function on the pharmacokinetics of donepezil HCl. Phase II and III studies conducted in the USA have shown that donepezil (5 mg or 10 mg once daily) produces statistically significant improvements in cognition and global Methods function in patients with Alzheimer's disease [6] [7] [8] [9] . Its clinical efficacy and minimal side-effect profile are thought Subjects to be related to its specific inhibition of AChE in the areas Ten male volunteers with stable, chronic, compensated of the brain affected by the cholinergic deficit that typifies cirrhosis of the liver and ten age-and sex-matched healthy this disease [1, 2, 5] .
controls were enrolled in the study. Eligible subjects in both Assessment of the potential impact of hepatic dysfunction groups were between 18 and 65 years of age and within on the pharmacokinetic and adverse event profiles of 30% of ideal weight for their height and body build, based on the Metropolitan Insurance Company Height and Weight Tables (1983) . All subjects were required to be free from clinically significant gastrointestinal, renal, respiratory, endoevacuated containers. Immediately after collection, the samples were centrifuged (2000 g) for 15 min at 4°C. The crine, haematological, neurological, psychiatric or cardiovascular system abnormalities. None of the study subjects plasma was then removed and transferred into 10 ml polypropylene storage tubes. Samples were stored in an had a known or suspected recent history of alcohol or drug misuse or a positive urine drug screen at the time of entry upright position at −20°C until analysis. Plasma concentrations of donepezil HCl were measured using highinto this study.
Healthy subjects were required to have no evidence of performance liquid chromatography (HPLC) with UV detection (315 nm) [12] . The lower detection limit of the hepatic dysfunction in clinical or laboratory evaluations (i.e. all tests and examination results within normal limits). assay was 2.0 ng ml −1 .
Subjects with liver cirrhosis were selected from patients with a history and clinical evidence of stable, compensated Pharmacokinetic assessments alcoholic cirrhosis of the liver, confirmed by percutaneous Characterization of donepezil pharmacokinetics was conducbiopsy or liver imaging studies. Subjects with clinical ted using plasma drug concentration data from the collected evidence of significant ascites, evidence of hepato-renal samples. All volunteers who received test medication and syndrome, extrahepatic bile duct obstruction, or acute or who had analytical samples collected were evaluated. The chronic hepatitis were excluded from entry.
peak concentration (C max ) and the time of occurrence of The study was conducted in accordance with the C max (t max ) were computed from the observed values. In Declaration of Helsinki, and the study protocol was approved cases where C max occurred at multiple time-points, the t max by the Institutional Review Board of the New Orleans selected was the earliest. The terminal disposition phase was Clinical Research Center. All subjects gave written informed identified by visual inspection of each subject's semiconsent prior to participation in any study activities.
logarithmic donepezil plasma concentration-time curve. The terminal disposition phase was selected for timepoints Protocol from 24-to 120-h post-dose. The elimination rate constant (l z ) was estimated as −2.303 times the slope of the best-fit This was an open-label, non-randomized study of single linear regression line of the terminal phase. The terminal doses of donepezil HCl. Eligible subjects completed a half-life (t D ) was calculated as 0.693/l z . The area under the screening assessment no more than 2 weeks prior to plasma concentration-time curve from 0 to 120 h receiving study medication. Subjects were admitted to the (AUC (0-120) ) was calculated using the trapezoidal rule and study site in the evening approximately 12 h prior to drug extrapolated to time infinity (AUC (0-2 ) ) by adding the ratio administration. A single 5 mg dose of donepezil HCl was of the last measurable concentration (at 120 h) to l z . Timeadministered with 250 ml of water at about 08:00 h, averaged total body clearance (CL T /F) was calculated as following an 8-h overnight fast. The subjects remained in the ratio of the administered dose to AUC (0-2 ) , and an upright position (>45°angle from supine) and continued apparent volume of distribution (V lz /F) was calculated as to fast from food and fluids for 4 h after drug administration.
the ratio of CL T /F to l z , where the factor F accounts for All study participants remained at the study site for 48-h bioavailability. following drug administration. During this time, blood samples were collected at specified intervals for the Safety assessments measurement of donepezil in plasma. The subjects were discharged from the study site on the morning of day 3, All adverse events reported spontaneously by the subjects after the collection of a blood sample at the 48-h timeand/or observed or elicited during physical examination point. They returned to the study site each morning for the were documented together with times of onset and cessation, next 3 days to provide additional blood samples for plus assessments of severity and causality. Vital signs were pharmacokinetic analysis. End-of-study physical and laboramonitored at regular intervals during the in-house portion tory evaluations were conducted on the morning of day 6, of each treatment period. Laboratory evaluations were following the 120-h sampling time-point.
conducted at the start of the treatment period. Throughout the study, the subjects abstained from physical activity other than normal walking. Healthy subjects had Statistical analysis received no prescription, non-prescription or investigational drugs for at least 1 month prior to entering the trial. OverOne-way analysis of variance (ANOVA) was used to the-counter products, illicit drugs and alcohol consumption compare the pharmacokinetic parameters of the hepatically were not permitted from 72 h prior to admission until the impaired and normal subjects. Confidence intervals (95%) end of the treatment period. Subjects with hepatic cirrhosis were computed for the mean difference between the two were allowed to continue receiving medications considered subject groups. All statistical tests were two-tailed at the essential for their well-being. 0.05 significance level.
Sample collection and analysis Results
Venous blood samples for the determination of donepezil Subjects concentrations in plasma were collected 1 h prior to, and at  1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48 , 72, 96 and 120 h after Ten male patients with stable hepatic cirrhosis and ten healthy, age-and sex-matched controls were enrolled into drug administration. Blood was collected in 7 ml heparinized, , not statistically significant. CL T /F, V lz /F and l z were essentially identical in the two groups. In the majority of respectively, in the normal subjects. All 20 volunteers completed the study without incident.
normal and hepatically impaired subjects, donepezil was no longer detectable in plasma 120 h after drug administration.
Pharmacokinetics of donepezil Safety
The mean plasma concentration-time curves following administration of a single 5-mg oral dose of donepezil to Donepezil was well tolerated by all subjects and no changes healthy subjects and to patients with cirrhosis are shown in in vital sign parameters were observed during the course of Figure 1 . Data from one hepatically impaired subject was the study. Several hepatically impaired patients had ECG excluded from the pharmacokinetic analysis as a consequence characteristics at baseline consistent with their medical of his HPLC plasma analysis in which a large extraneous condition. These were primarily non-specific ST-T wave peak eluted with a similar retention time as donepezil. The changes. None of the changes was clinically significant or peak was subsequently found to be caused by spironolactone, related to treatment. which was being concomitantly administered for the treatment of peripheral oedema. Discussion No statistically significant differences in donepezil pharmacokinetics were observed between the hepatically impaired
The involvement of cytochrome P-450 isoenzymes in the patients and the normal subjects, with the exception of C max metabolism of donepezil combined with first-pass metab-( Table 2 ). The hepatically impaired group showed a statistiolism following oral dosing has highlighted the importance cally higher mean C max value of 6.6 ng ml −1 compared of investigating whether or not hepatic impairment produces with the control group, which had a mean C max value of any changes in the pharmacokinetic profile of the drug. The pharmacokinetic results summarized here suggest that compromised hepatic function appears to increase plasma levels of donepezil relative to those achieved in healthy ageand sex-matched control subjects. However, of the pharmacokinetic parameters examined, only C max increased significantly. The observed difference (37.5%) was greater than the 20% range that is generally considered to represent clinical significance. This may in part reflect the variability associated with the small subject groups used in this study. This finding is also tempered because the differences observed following single-dose administration are expected to become less prominent once steady state is reached. In addition, the pharmacokinetic stability of donepezil in hepatically impaired patients is further supported by the fact that the AUC and t D values showed much smaller and non- The stability of donepezil's pharmacokinetic profile is to healthy subjects (n=10) and to patients with compromised hepatic function (n=9).
explained by its relatively slow clearance from plasma, relatively low levels, with the consequence that its pharmaco- Alzheimer's disease. Neurology 1998; 50: 136-145. 9 Rogers SL, Doody RS, Mohs R, Friedhoff LT, the Donepezil
